维普期刊资源整合服务平台（V6.5）

54篇 您的检索式：作者名="TANNOCK I F"

选中清除导出查看参考文献查看引证文献引用追踪共3页首页上一页第1页下一页末页 /3 跳转

	题名	作者	年代	出处	被引量
1	Repopulation of cancer cells during therapy:an important cause of treatment failure显示文摘	KIM J J TANNOCK I F	2005	Nat Rev Cancer2005，5，7：	1
2	Repopulation in murine breast tumors during and after sequential treatments with cyclo- phosphamide and 5-fluorouracil显示文摘	WU L TANNOCK I F	2003	Cancer Res2003，63，9：	1
3	Cognitive impairment associated with chemotherapy for cancer:report of a workshop显示文摘	Tannock I F Ahles T A Ganz P A	2004	J Clin Oncol2004，22，11：	1
4	Drug penetration in solid tumours显示文摘	MINCHINTON A :I TANNOCK I F	2006	Nat Rev Cancer2006，6，8：	1
5	Population kinetics of carcinoma cells, cap- illary endothelial cells, and fibroblasts in a transplanted mouse mammary tumor显示文摘	TANNOCK I F	1970	Cancer Res1970，30，10：	1
6	Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer显示文摘	Tannock I F de Wit R Berry W R	2004	N Engl J Med2004，351，15：	1
7	A phase Ⅱ trial of docetaxel and cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma显示文摘	McCarthy J S Tannock I F Degendorfer P	2002	Oral Oncol2002，38，7：	1
8	Docetaxel plus prednisone or mitoxantrone plus predni- sone for advanced prostate caneer显示文摘	Tannock I F de Wit R Berry W R Horti J Pluzanska A Chi K N	2004	N Engl J Med2004，351，：	1
9	Dose escalation of gemcitabineconcomitant with radiation and cisplatin for nonsmall cell lung cancer : aphase 1 -2 study显示文摘	Momm F Kaden M Tannock I	2010	Cancer2010，116，48：	1
10	Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma显示文摘	Ma B B Tannock I F pond G R	2002	Cancer2002，95，12：	1
11	Scheduling of radiation and chemo therapy for limited-stage small-cell lung cancer: Repopulation as a cause of treatment failure?显示文摘	Brade A M Tannock I F	2006	J Clin Oncol2006，24，24：	1
12	Selective estrogen receptor modulators as inhibitors of reputation of human breast cancer cell lines after chemotherapy显示文摘	Li W Tannock I F	2003	Clin Cancer Res2003，9，1：	1
13	Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer显示文摘	TANNOCK I F DE WIT R BERRY W R	2004	N Engl J Med2004，351，15：	1
14	Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer显示文摘	Tannock I F de Wit R Berry W R	2004	N Engl J Med2004，351，：	1
15	Bone Metastases:Pathophysiology and Management Policy显示文摘	Nielsen O S Munro A J Tannock I F	1991	J Clin Oncol1991，9，3：	1
16	Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer 显示文摘	TANNOCK I F DE WIT R BERRY W R	2004	N Engl J Med2004，351，15：	1
17	Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points 显示文摘	TANNOCK I F OSOBA D STOCKLER M R	1996	J Clin Oncol1996，14，6：	1
18	Acid pH in tumors and its potential for therapeutic exploitation显示文摘	Tannock I F Rotin D	1989	Cancer Research1989，49，43：	1
19	Influence of cell concentration in limiting the therapeutic benefit of P-glyceprotein reversal agents 显示文摘	Tunggal J K Ballinger J R Tannock I F	1999	lnt J Cancer1999，81，5：	1
20	The penetration of anticancer drugs through tumor tissue as a function of cellu- lar adhesion and packing density of tumor cells 显示文摘	Grantab R Sivananthan S Tannock I F	2006	Cancer Res2006，66，2：	1

返回顶部每页显示：

共3页首页上一页第1页下一页末页 /3 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示